Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer

NCT04906044 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Tislelizumab
Locally Advanced Rectal Cancer
Total Neoadjuvant Treatment
PD-1

Interventions

DRUG: Sintilimab

Sponsor

The First Hospital of Jilin University